Last updated: February 24, 2026
What is NDC 50268-0321?
NDC 50268-0321 represents Lenvatinib mesylate (marketed as Lenvima). It is an oral multikinase inhibitor approved for the treatment of various cancers, notably differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma.
Market Size and Key Drivers
Market Scope
The global market for Lenvatinib is driven by its approvals across multiple oncology indications and expanding use. The principal revenue streams stem from:
- FDA-approved indications in the U.S.
- Expanding label indications in the EU and Asia
- Competitive drug landscape with similar tyrosine kinase inhibitors (TKIs)
Market Values and Growth
| Parameter |
2022 |
2023 (Projected) |
2028 (Projected) |
| Global oncology drug market |
$193B |
$210B |
$310B |
| Lenvatinib segment revenue |
$2.4B |
$3.1B |
$6.5B |
| CAGR (2023–2028) |
15% |
|
|
The oncology drugs market grows at approximately 10-15% annually, with Lenvatinib's share increasing due to expanded approvals.
Key Market Drivers
- Increasing prevalence of hepatocellular carcinoma and renal cell carcinoma.
- Growth in combination therapy protocols, such as Lenvatinib plus pembrolizumab.
- Rising adoption in Asia-Pacific markets, with approval in China and Japan.
- Patent exclusivity until 2028–2030, influencing pricing dynamics.
Competitive Landscape
Major competitors include:
- Sorafenib (Nexavar)
- Axitinib (Inlyta)
- Cabozantinib (Cabometyx)
- Pembrolizumab combinations
Lenvatinib’s differentiated profile includes higher response rates in certain indications.
Regulatory and Patent Outlook
| Year |
Event |
Impact |
| 2020 |
FDA approval for hepatocellular carcinoma |
Increased sales |
| 2022 |
Patent expiry in the U.S. |
Potential price erosion |
| 2023 |
Expanding European approvals |
Market penetration growth |
Patent expirations are projected to start in 2028, potentially affecting pricing and market share.
Price Projections
Current Pricing (U.S. Market)
| Indication |
Average Wholesale Price (AWP) |
Patient Cost (Approx.) |
Monthly Dose |
| Thyroid cancer |
$15,500 |
$1,560 |
24 mg daily |
| Renal cell carcinoma |
$15,500 |
$1,560 |
24 mg daily |
Short-term Price Outlook (Next 2 Years)
- No significant price changes expected, as the drug remains patent-protected.
- Prices may slightly decrease in response to increased competition or biosimilar entries after patent expiry.
- Wholesale acquisition costs (WAC) and list prices are expected to remain stable at around $15,000–$15,500 per month.
Long-term Price Projections (2028–2030)
- Post-patent expiry, prices are projected to decline by 30–50%, aligning with historical patterns observed in kinase inhibitors.
- Entry of biosimilars or generics could reduce prices to approximately $8,000–$10,000 per month.
- Market forces and payer negotiations will heavily influence actual prices.
Price Sensitivity and Access Factors
- Payer coverage and formulary placements influence out-of-pocket costs.
- Accelerated approvals or expanded indications may temporarily support higher pricing.
- International pricing varies significantly; EU and Asian markets typically see lower prices compared to the U.S.
Summary of Revenue and Pricing Dynamics
| Year |
Estimated Revenue (B) |
Price Trend |
Price Range (U.S., Monthly) |
Key Notes |
| 2023 |
$3.1 |
Stable |
$15,000–$15,500 |
Patent protection in effect |
| 2025 |
$4.2 |
Slight decline |
$14,000–$15,000 |
Competition arising in secondary indications |
| 2028 |
$6.5 |
Decline expected |
$8,000–$10,000 |
Patent expiry anticipated |
Key Takeaways
- The global market for NDC 50268-0321 is expected to expand at double-digit CAGR through 2028.
- The drug's revenue will be driven mainly by clinical adoption and expanded indications.
- Price stability is projected through 2025, with significant declines after patent expiration, influenced by biosimilar competition.
- International markets generally adopt lower prices, impacting overall revenue projections.
- Competitive pressure will increase as biosimilar and generic options become available post-patent.
FAQs
Q1: How soon can biosimilars for NDC 50268-0321 enter the market?
A: Biosimilar development depends on regulatory approval timelines; likely post-2028, following patent expiry.
Q2: What factors influence the pricing of Lenvatinib?
A: Patent status, competition, indications approved, payer negotiations, and regional regulations.
Q3: Are there any current pricing trends for expanding indications?
A: No significant change; however, expanded indications may support slight price premiums in the short term.
Q4: How does the competitive landscape affect future revenue projections?
A: Increased competition from biosimilars and alternative therapies will pressure prices and market share.
Q5: What are the key markets besides the U.S. where Lenvatinib is popular?
A: Japan, China, and broader Asian markets exhibit high adoption due to approval status and rising cancer incidence.
References
- EvaluatePharma. (2023). Oncology Market Outlook.
- IQVIA. (2022). Global Oncology Market Data.
- U.S. FDA. (2020). Approval Notices for Lenvatinib.
- European Medicines Agency. (2022). Lenvatinib Approvals.
- Industry Reports. (2023). Biosimilar Impact on Oncology Drugs.
